PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1748688
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1748688
Predictive Genetic Testing and Consumer Genomics Market size was valued at USD 4,790.43 Million in 2024, expanding at a CAGR of 12.71% from 2024 to 2032.
Predictive genetic testing involves analyzing an individual's DNA to assess the risk of developing certain genetic conditions before symptoms appear. It helps identify gene mutations linked to diseases like cancer or heart conditions, enabling proactive healthcare decisions.
Consumer genomics refers to direct-to-consumer genetic testing services that provide insights into ancestry, traits, wellness, and health risks. These tests are typically purchased online and conducted at home using saliva samples. While predictive testing is often used in clinical settings, consumer genomics offers broader accessibility, though it may lack the clinical accuracy or guidance provided by healthcare professionals. Both contribute to personalized healthcare approaches.
Predictive Genetic Testing and Consumer Genomics Market- Market Dynamics
Rising Demand for Personalized Healthcare
The growing emphasis on personalized healthcare is a key driver for the predictive genetic testing and consumer genomics market. Individuals are increasingly seeking tailored health insights to manage risks and make informed lifestyle or treatment decisions. Predictive genetic testing supports early detection and prevention of inherited diseases, while consumer genomics offers convenient access to genetic information. The rising awareness of genetic predispositions, combined with technological advancements in genomics and reduced testing costs, is fueling consumer interest. This trend is further supported by the integration of genomics into digital health platforms and wellness-focused services.
Predictive Genetic Testing and Consumer Genomics Market- Key Insights
According to our research analyst, the global Predictive Genetic Testing and Consumer Genomics Market is expected to develop at a CAGR of approximately 12.71% between 2024-2032.
Segmented by Test in 2023, the Consumer genomics category dominated the market.
Based on Application, the Breast & Ovarian Cancer segment generated the most income in 2023.
On the basis of region, in 2023, North America was the region with the highest revenue.
The global Predictive Genetic Testing and Consumer Genomics Market is divided into four categories: Test, Application, setting and Region.
The predictive genetic testing and consumer genomics market is segmented by type into Predictive Testing, Consumer Genomics, and Wellness Genomics. Predictive testing focuses on identifying genetic predispositions to various inherited diseases before symptoms appear, enabling preventive care and early interventions. Consumer genomics provides users with direct access to genetic information related to ancestry, traits, and potential health risks through at-home testing kits. Wellness genomics emphasizes optimizing lifestyle and nutrition based on individual genetic profiles. Among these, Consumer Genomics holds the dominant share due to its accessibility, affordability, and growing consumer interest in personal health and ancestry insights. The proliferation of direct-to-consumer platforms, coupled with increased marketing and digital outreach, has made consumer genomics widely popular, driving significant market growth across regions.
By application, the predictive genetic testing and consumer genomics market is segmented into Breast & Ovarian Cancer, Cardiovascular Screening, Diabetic Screening & Monitoring, Colon Cancer, Parkinsonism/Alzheimer's Disease, Urologic/Prostate Cancer Screening, Orthopedic & Musculoskeletal, Other Cancer Screening, and Other Diseases. Each application area focuses on identifying genetic markers associated with disease risk, allowing for early detection and preventive care. Among these, Breast & Ovarian Cancer represents the dominant segment, driven by strong public awareness, the prevalence of BRCA1 and BRCA2 genetic mutations, and targeted testing programs. High-profile advocacy, advancements in genetic diagnostics, and the integration of these tests into routine clinical screenings have significantly contributed to the segment's growth, making it a primary focus area for both healthcare providers and genetic testing companies.
Predictive Genetic Testing and Consumer Genomics Market- Geographical Insights
Geographically, the Predictive Genetic Testing and Consumer Genomics Market is distributed throughout North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa. These regions are further divided based on the nations bringing in business.
North America is the leading region in the predictive genetic testing and consumer genomics market, primarily driven by the United States. The region benefits from advanced healthcare infrastructure, strong research and development initiatives, and high consumer awareness regarding genetic testing. Companies like 23andMe, AncestryDNA, and Myriad Genetics are key players fueling market growth through innovative product offerings and direct-to-consumer models. Additionally, favorable regulatory support, increasing adoption of precision medicine, and the integration of genetic testing into mainstream healthcare have expanded access and demand. Insurance coverage for genetic screening, particularly for hereditary cancers, also supports clinical adoption. The U.S. dominates due to its proactive healthcare policies, while Canada is emerging steadily, aided by government-funded genomics research. Overall, North America's technological leadership and consumer engagement drive its market dominance.
Europe stands as the second most dominant region in the predictive genetic testing and consumer genomics market, led by countries such as the United Kingdom, Germany, and France. The region benefits from strong government support for genomics research, increasing healthcare digitization, and growing public interest in preventive health solutions. National genomics strategies, like the UK's 100,000 Genomes Project, have significantly boosted awareness and infrastructure for genetic testing. Moreover, stringent data privacy regulations under GDPR enhance consumer trust in genetic services. European countries are also investing in personalized medicine and integrating predictive testing into routine health screenings. Rising cancer prevalence and cardiovascular concerns have further encouraged genetic screening initiatives. Companies operating in Europe are focusing on expanding their service offerings and accessibility through partnerships with public health systems, solidifying the region's strong market position.
The competitive landscape of the Predictive Genetic Testing and Consumer Genomics market is shaped by both established biotechnology and diagnostics firms as well as agile innovators. Key players like 23andMe, Myriad Genetics, Roche, Abbott, Agilent Technologies, and Thermo Fisher Scientific dominate the market with advanced genomic platforms and broad product portfolios. These companies invest heavily in R&D and regulatory compliance to enhance test accuracy, expand applications, and maintain competitive advantage. Emerging firms and research-driven companies like BGI, Illumina, and Bio-Rad focus on high-throughput sequencing and cost-efficiency.
In March 2025, 23andMe filed for Chapter 11 bankruptcy, citing financial challenges and a significant data breach affecting 6.9 million users. The company announced the closure of its San Francisco office and issued layoff notices to 250 employees as part of its restructuring efforts.
In February 2025, Myriad Genetics entered into a strategic collaboration with PATHOMIQ to integrate AI technology into its oncology offerings. This partnership aims to enhance prostate cancer diagnostics by combining PATHOMIQ's AI platform with Myriad's Prolaris test, facilitating more precise treatment decisions.
In August 2024, Illumina unveiled a strategy to accelerate revenue growth over the next three years, focusing on innovations in multiomics and single-cell sequencing. The company also announced a research partnership with the Broad Institute to advance single-cell sequencing technologies.